Cube Biotech
Didier Dargent is a seasoned executive with extensive experience in the healthcare sector, currently serving as the CEO and Board Member of Cube Biotech since March 2023. Dargent has held significant roles at prominent organizations, including as an Operating Partner at ArchiMed, Board Observer at PlasmidFactory GmbH, and Board Member at Title21 Health Solutions. Previously, Dargent excelled in leadership positions at Novartis Oncology, where responsibilities included advancing Cell & Gene Therapy initiatives across multiple regions, and at Servier, where management of substantial turnover and staff resulted in significant market growth and organizational improvements. Educational qualifications include dual Executive MBAs from INSEAD and Tsinghua University, an MSc in Pharmaceutical and Biotechnology Management from ESCP Business School, and a PhD in Pharmacy from Aix-Marseille University.
This person is not in any teams
This person is not in any offices
Cube Biotech
Cube Biotech is a contract research organization of membrane protein scientists offering non-GMP services for many applications. We assist in protein preparation, biophysical target characterization, and structure determination by cryo-EM or assay development. Our USP is a vast synthetic copolymer portfolio, enabling more reliable membrane protein research. Copolymers offer, in contrast to detergents, a broad and native picture of your target. Discover endless customization possibilities with our Protein Services – your project, your way, as easy as building with Lego bricks! Build frameworks that are easily incorporated into your own processes. Choose between FTE-based, fee-for-service-based, and milestone-based models. We are looking for long-term collaborations with industrial and academic partners. Contact us to learn more.